

Special Issue

Developing Recombinant Vaccines and Immunotherapy Strategies for Emerging Viral Diseases

Message from the Guest Editors

Emerging viral infections continue to pose serious global health hazards, frequently resulting in extensive epidemics with limited therapeutic options. The fast development and adaptation of viruses emphasizes the critical need for novel ways to prevent and treat them. To this end, recombinant vaccination technologies and enhanced immunotherapy tactics have emerged as promising approaches to overcoming these obstacles. This Special Issue aims to highlight innovative studies and reviews which focus on the development of recombinant vaccines and newly developed immunotherapeutic treatments for re-emerging viral infections. Topics of interest include novel vaccine platforms (such as viral vectors, DNA/RNA-based vaccines, and protein subunit vaccines), advancements in antibody therapies, immune modulation techniques, and strategies for enhancing vaccine efficacy against highly mutable viruses.

Guest Editors

Dr. Emmanuel Datan

Vascular Program, Institute for Cell Engineering and Department of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Prof. Dr. Athanasios Tsakris

Department of Microbiology, Medical School University of Athens, Athens, Greece

Deadline for manuscript submissions

31 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/240709

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).